Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Univ. of Texas Southwestern Medical Center Bcl-2 compound 35
- Development stage
- Unknown
- Lead developer
- UT Southwestern Medical Center
01
Overview
Univ. of Texas Southwestern Medical Center Bcl-2 compound 35: sourced facts only. name: "Our NMR analysis showed that compound 35 directly binds Bcl-2 and specifically inhibits the interaction between the Bcl-2 and Beclin 1 BH3 domains without disruption of the Bcl-2-Bax BH3 interaction." [PMID:36105331]; target: "Our NMR analysis showed that compound 35 directly binds Bcl-2 and specifically inhibits the interaction between the Bcl-2 and Beclin 1 BH3 domains without disruption of the Bcl-2-Bax BH3 interaction." [PMID:36105331]; developer: "University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States." [PMID:36105331]
02
Targets
BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on Univ. of Texas Southwestern Medical Center Bcl-2 compound 35.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Univ. of Texas Southwestern Medical Center Bcl-2 compound 35.